89bio: standing out in the NASH crowd
89bio thinks its FGF21 analog could be superior to other compounds that aim to treat the underlying metabolic causes of NASH
89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be superior to others in development.
The company launched last year with a $60 million series A round and two discarded compounds from Teva Pharmaceutical Industries Ltd. to address the absence of marketed drugs to treat non-alcoholic steatohepatitis.
89bio’s lead candidate, BIO89-100 (TEV-47948), is an glycopegylated analog of the metabolic hormone